皇家制药版税
RPRX
60.96
+1.34
+2.25%
皇家制药版税
US · RPRX
#759 按市值排名
上市于 2020
60.96
+1.34
+2.25%
实时 - 追踪5344个代码 - 心跳于420秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了4家。
- 机构持股总比例下降了0.7个百分点。
机构持股
- 机构持股比例
- 84.81% -0.66pp
- 机构数量
- 816 -4
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund72.28%
Individual/Insider6.10%
Hedge Fund5.40%
Public Company2.50%
Government Pension Fund1.56%
Sovereign Wealth Fund1.26%
Private Company1.03%
Family Office/Trust0.27%
Insurance Company0.21%
Other9.38%
主要股东 截至 2026-06-30
Capital Research
10.70% · 47.65M 股
Morgan Stanley Investment Management Inc.
8.38% · 37.31M 股
BlackRock
6.25% · 27.83M 股
Mario Giuliani
4.80% · 21.37M 股
FMR
4.32% · 19.22M 股
State Street Global Advisors
2.77% · 12.34M 股
T. Rowe Price Group, Inc.
2.51% · 11.19M 股
Swedbank Robur Fonder AB
2.41% · 10.73M 股
Baillie Gifford
2.25% · 10.02M 股
Geode Capital Management, LLC
1.81% · 8.06M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 23次买入 · 27次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Mario Giuliani | Director | 4.80% |
| Pablo Legorreta | Founder, Chairman of the Board & CEO | 1.10% |
| Christopher Hite | Vice Chairman & Executive VP | 0.07% |
| Gregory Norden | Independent Director | 0.04% |
| Bonnie Bassler | Independent Director | 0.02% |
| Errol De Souza | Independent Director | 0.01% |
| Ted Love | Independent Director | 0.01% |
| Catherine Engelbert | Independent Director | 0.01% |
| Terrance Coyne | Chief Financial Officer | 0.01% |
| David Hodgson | Independent Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-04 | Marshall Urist | Executive VP and Head of Research & Investments | Automatic Disposition | -4,126 | $57.10 |
| 2026-09-29 | Bonnie Bassler | Independent Director | Other Acquisition | +642 | $58.41 |
| 2026-09-27 | Marshall Urist | Executive VP and Head of Research & Investments | Automatic Disposition | -4,126 | $57.88 |
| 2026-09-21 | Christopher Hite | Vice Chairman & Executive VP | Automatic Disposition | -100,000 | $58.51–58.93 |
| 2026-08-18 | Christopher Hite | Vice Chairman & Executive VP | Other Disposition | -16,800 | -- |
| 2026-08-17 | Christopher Hite | Vice Chairman & Executive VP | Automatic Disposition | -100,000 | $59.97 |
| 2026-08-12 | Terrance Coyne | Chief Financial Officer | Automatic Disposition | -11,002 | $58.59–59.14 |
| 2026-08-06 | Marshall Urist | Executive VP and Head of Research & Investments | Other Derivative Disposition | -3,000 | -- |
| 2026-08-06 | Terrance Coyne | Chief Financial Officer | Other Disposition | -18,500 | -- |
| 2026-08-06 | Pablo Legorreta | Founder, Chairman of the Board & CEO | Other Derivative Disposition | -30,000 | -- |
| 2026-08-04 | Christopher Hite | Vice Chairman & Executive VP | Other Acquisition | +11,002 | -- |
| 2026-08-04 | Marshall Urist | Executive VP and Head of Research & Investments | Other Acquisition | +8,252 | -- |
| 2026-08-04 | Terrance Coyne | Chief Financial Officer | Other Acquisition | +11,002 | -- |
| 2026-08-04 | Pablo Legorreta | Founder, Chairman of the Board & CEO | Other Acquisition | +65,216 | -- |
| 2026-06-30 | Marshall Urist | Executive VP and Head of Research & Investments | Automatic Disposition | -9,099 | $55.88 |
| 2026-06-29 | Christopher Hite | Vice Chairman & Executive VP | Automatic Disposition | -130,000 | $56.44–57.10 |
| 2026-06-29 | Bonnie Bassler | Independent Director | Other Acquisition | +689 | $54.40 |
| 2026-06-23 | Marshall Urist | Executive VP and Head of Research & Investments | Automatic Disposition | -9,098 | $55.18 |
| 2026-06-22 | Christopher Hite | Vice Chairman & Executive VP | Automatic Disposition | -150,000 | $54.11–54.47 |
| 2026-06-04 | David Hodgson | Independent Director | Other Acquisition | +4,545 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
皇家制药版税 讨论区 0 条评论